Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pelvic Inflammatory Disease
Conditions
Pelvic Inflammatory Disease
Trial Timeline
Apr 1, 2003 → Oct 1, 2004
NCT ID
NCT00683865About Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)
Ofloxacin + Avelox (Moxifloxacin, BAY12-8039) is a phase 3 stage product being developed by Bayer for Pelvic Inflammatory Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00683865. Target conditions include Pelvic Inflammatory Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00683865 | Phase 3 | Completed |
Competing Products
11 competing products in Pelvic Inflammatory Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Solifenacin + Placebo | Astellas Pharma | Approved | 85 |
| BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Tanezumab + Placebo | Pfizer | Phase 2 | 51 |
| Azithromycin | Pfizer | Phase 3 | 76 |
| Vaginal estrogen + Placebo | Pfizer | Pre-clinical | 22 |
| Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet | Pfizer | Phase 2 | 51 |
| Conjugated Estrogens Cream + Placebo Cream | Pfizer | Approved | 84 |
| BAY1834845 + Placebo | Bayer | Phase 1 | 30 |
| Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole | Bayer | Phase 3 | 74 |
| Dienogest (BAY86-5258, Visanne) | Bayer | Pre-clinical | 20 |
| Sevoflurane + propofol + remifentanil | Baxter | Approved | 82 |